|Articles|June 10, 2016
Oral Dose Development for Macromolecules
Author(s)Catalent Pharma Solutions
#wpbut {border: 3px solid #245998; border-radius:40px; border-color: #245998; padding: 15px 30px; font-size:15px !important;} #wpbut:hover {background: #15355a; color: #fff !important; transition: .5s;}
Related Content
Trending on Pharmaceutical Technology
1
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
2
The FDA Moves to Modernize Drug Manufacturing Registration
3
PharmTech Weekly Roundup–July 10, 2026
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5